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A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic
cidofovir analog, and localized foscarnet. Mutations conferring ganciclovir and cidofovir resistance were detected in CMV from
the aqueous fluid but not in CMV from plasma. Quantifying CMV from aqueous fluid was valuable for monitoring the clinical
response and predicting resistance.
CASE REPORT
A39-year-old Asian female with Burkitt’s lymphoma wascompleting therapy with hyperfractionated rituximab, cy-
clophosphamide, vincristine, doxorubicin, and dexametha-
sone when she presented with neurological symptoms. Cyto-
megalovirus (CMV) was detected by a laboratory-developed
PCR test (LDT) (12) from her plasma and cerebrospinal fluid
(CSF), and intravenous (i.v.) ganciclovir was initiated. The
ophthalmology service noted that although she had no visual
symptoms, the patient had a small focus of CMV chorioretini-
tis nasally in the right eye and a larger lesion in the periphery of
the left eye. Due to a national foscarnet shortage, she was
treated with bilateral intravitreal ganciclovir injections (0.5
mg). Concurrent anterior chamber paracenteses were per-
formed, and aqueous fluid samples from both eyes were posi-
tive for CMV by the LDT. After 11 days, her systemic therapy
was switched to an investigational cidofovir analog (CMX001;
Chimerix, Durham, NC) due to a lack of clinical improvement
and increasing CMV loads in plasma. After 10 days on
CMX001, she was switched back to i.v. ganciclovir because she
developed ileus. After approximately 2 weeks of i.v. ganciclovir
and decreasing CMV loads in plasma, she was transitioned to
oral valganciclovir. Although her initial bilateral retinitis clin-
ically responded rapidly to a single ganciclovir injection and
her systemic therapy as described above, she showed evidence
of recurrence in her right eye approximately 2 months after
initial presentation (Fig. 1B). This recurrence initially re-
sponded to a repeat ganciclovir injection, but genotyping per-
formed from the aqueous sample revealed a mixture of wild-
type CMV and a population with a UL97 gene mutation
(C603R) conferring ganciclovir resistance. The plasma was
tested concurrently and showed only a wild-type population of
CMV. Once foscarnet became available, she was given intrav-
itreal injections (2.4 mg) every 2 weeks in her right eye, until
another recurrence about 4 months after initial presentation
which led to twice-weekly injections of foscarnet (Fig. 1C).
Repeat CMV genotyping from her right aqueous fluid revealed
yet another population of CMV with a UL54 gene mutation
(T503I) conferring resistance to both cidofovir and ganciclo-
vir. Having received a total of 43 injections in her right eye, the
patient was stable at 9 months from initial presentation. Her
left eye remained stable after the initial ganciclovir injection
and a consolidation foscarnet injection at 3 months postpre-
sentation, but it showed evidence of recurrence at approxi-
mately 6 months postpresentation (Fig. 2B). She received
twice-weekly foscarnet injections in the left eye and was stable
at 9 months postpresentation. She received a total of 36 injec-
tions in her left eye. She has not exhibited any evidence of
toxicity related to intravitreal injections. Throughout her
course, quantitative real-time PCR of aqueous fluid obtained
from weekly anterior chamber paracenteses was used to mon-
itor her response to therapy (Fig. 1 and 2, lower panels).
CMV chorioretinitis is a major cause of morbidity among
immunocompromised patients. Although antiviral medica-
tions (ganciclovir, foscarnet, and cidofovir) provide effective
treatment options for most patients, phenotypic resistance to
anti-CMV medications is reportedly 5 to 25% (3, 7). Sequenc-
ing of the CMV UL97 (phosphotransferase) and UL54 (DNA
polymerase) genes for mutations known to confer resistance is
performed to predict drug resistance to ganciclovir and all
three drugs (ganciclovir, foscarnet, and cidofovir), respectively
(1). Many documented UL97 and UL54 gene mutations have
now been reported in the literature, with various degrees of
phenotypic resistance (2, 5, 10). The UL97 C603R mutation has
been described previously, with a 3.6- to 8.3-fold decrease in
susceptibility to ganciclovir (4, 11). Not surprisingly, the hy-
brid wild-type and C603R mutation population present in our
patient behaved clinically like a ganciclovir-resistant popula-
tion. Although our patient received weeks of ganciclovir and 10
days of a cidofovir analog, she had received only one intraoc-
ular injection of ganciclovir in each eye prior to developing
intraocular resistance, and this mutation was not detected from
plasma CMV. In addition, the DNA polymerase mutation con-
ferring resistance to both drugs was identified only from aque-
ous fluid, as the plasma CMV was negative. For both instances,
it should be noted that multiple populations of resistant virus
Received 3 January 2012 Returned for modification 17 January 2012
Accepted 8 February 2012
Published ahead of print 15 February 2012
Address correspondence to Melissa B. Miller, mbmiller@unch.unc.edu.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00029-12
CASE REPORT
1796 jcm.asm.org 0095-1137/12/$12.00 Journal of Clinical Microbiology p. 1796–1799
could have been present, with only the predominant strain
being detected by the sequencing assay performed by the refer-
ence laboratory (Viracor, Lee’s Summit, MO). To our knowl-
edge there is only one report of an intraocular CMV genotype
that differs from the blood genotype, and this was obtained
from a vitreous biopsy specimen (14). It is likely that the fre-
quent changes in systemic antiviral therapy contributed to the
development of intraocular resistance.
For our patient, we performed quantitative real-time PCR on
aqueous humor to monitor our patient’s disease progression, sim-
ilar to previous reports of quantitative PCR in the evaluation and
monitoring of other intraocular viral infections (6, 8, 9, 13). Prim-
ers and probes used were previously described by Sanchez and
Storch (12). The quantifying standard was obtained from Ad-
vanced Biotechnologies (Columbia, MD), and viral load per ml
was extrapolated from the standard curve. As the volume of aque-
ous fluid was very limited, the fluid was diluted in nuclease-free
water to obtain 200 l for nucleic acid extraction. The dilution
factor was used in the final calculation of the quantitative result.
Figures 1 and 2 demonstrate that quantitative PCR performed on
aqueous fluid closely mirrors the clinical progression.
The clinical diagnosis of CMV retinitis can easily be con-
fused with other infectious processes, including acute retinal
necrosis caused by herpes simplex, progressive outer retinal
necrosis due to varicella zoster, and even toxoplasma chori-
oretinitis. Also, active progression of disease versus clinical sta-
bility and scarring can often be difficult to ascertain by clinical
exam alone. Historically, vitreous biopsy has been used to de-
finitively diagnose the intraocular pathogen in cases of chorio-
retinitis, but biopsy carries the risk of vitreous hemorrhage,
bacterial infection, and retinal detachment. We have demon-
strated that anterior chamber paracentesis, a much easier and
FIG 1 Right eye. (Upper panel) Images of right eye obtained using a digital fundus camera (Zeiss, Inc., Dublin, CA). After initial ganciclovir injection,
the patient’s clinical course was stable by day 50, with mild pigmentary changes and whitening nasal to the optic nerve (A). An initial recurrence at day
65 with increased retinal whitening (B) coincided with increased viral load, and a more severe recurrence with extensive retinal hemorrhages and
whitening extending to the optic nerve at day 105 (C) was also mirrored by greatly increased viral load. Following initiation of twice-weekly ganciclovir
injections, the patient’s viral load decreased and her previously active retinitis evolved into a stable scar (D). (Lower panel) Quantitative viral load of
aqueous fluid over time.
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safer procedure, can be used to obtain a diagnostic specimen
when the clinical exam is equivocal or when the disease seems
to be progressing despite treatment. Specifically, we suggest
that (i) because quantified viral loads seemed to closely mirror
the clinical progression, aqueous paracentesis with quantita-
tive PCR may be a valuable adjuvant diagnostic procedure,
even in the absence of anterior segment inflammation, to de-
termine progression in clinically equivocal scenarios and (ii)
aqueous fluid can be used to obtain a genotypic profile in the
evaluation of possible resistance and, because of the relative
ease and low risk of collection, may be preferable to a vitreous
sample (15). This case also suggests the importance of directly
evaluating the intraocular fluid, as our patient’s intraocular
CMV resistance profile differed significantly from her systemic
genotype. While currently not performed frequently in the di-
agnosis and treatment of CMV retinitis, the adoption of this
practice may lead to both earlier and more effective treatment
for chorioretinitis. Finally, we have demonstrated that repeated
foscarnet injections, totaling 43 and 36 injections in our pa-
tient’s right and left eyes, respectively, were effective and did
not result in any frank toxicity.
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